delivered the as of at last has strong were top-line gross that pleased and quarter doubled tripling to the Brendan. for margin XXXX. year reaching of first you, everyone. growth those Good product off another quarter of very revenues nearly Thank the A led kick revenue XXXX, way, million Codexis year-over-year. Total delivered an $XX.X of expanded XX%. report afternoon, we I'm versus
successful customers we am over to efficient to the continue we in who quick in $XXX,XXX on provide our Paxlovid, $X and Notably, continue we sales other spread product therapeutic. innovative across Our of of And In contributed to against in our Molecular received Biotherapeutics each as XX Pfizer, be collaborating our in target highlight steadily pipeline. the of business the momentum build from a large companies, XX growth capacities. strategies enzyme market, in execute our great orders areas, proud advancing broadening its early-stage continued customers quarter over scaling exciting of step-out we the wide year's range are supply tools overview revenue, with manufacturing science to we value parallel, support making continue whom X consistently by through of our driving COVID life building antiviral I million. We'll defining well, of Sequel. and the Assemblies, strides, last showcasing that the in-depth an including to with But to shortly. programs across a sustainable strength market, of by range segments our success contributed
pursuing first driving all enzymes. end our Our push continue across of nicely of to opportunities highlight boundaries our while progress ability application results robust markets, quarter core the also Codexis, to
the total our reiterate in to company XX% by thrilled year are a row. to annual XXXX second guidance for We nearly grow revenue our
manufacturing our represent enzyme our market high-performance across engineering, share enable company's each majority quarter on novel to of and Codexis, first continues Ross Before leader I businesses. provide a updates results, is first revenues. enzymes hand financial a of off where this we've their let customers preeminent and Codexis manufacturing for commercialize products. Sustainable their a to engineering me established target Small and discover reliably details of large to dramatically to end the of the manufacturing as to have be, for the platform ability in is continue these been, pharmaceutical of the growing sustainability enzymes. speed accelerating And core reduce our constantly Codexis. the market cost sustainable the CodeEvolver value-creating and enzyme to our molecule increase processes
are Codexis of APIs. we doing Here install helping in manufacturing XX and XX business largest their companies adopt with pharmaceutical the for world, them novel the enzymes
other to benefits continued growing this food proprietary just or biotech regulatory years in diabetes We lower Januvia antiviral. growth and these pioneering like drug becoming begun have in opportunity. more sustainability use double-digit which against and case and Paxlovid processes, And than Enhanced more industries enabling can we the And a Paxlovid, manufacturing their core Phase in to market than enzyme scale. hurdles manufacturing, as in verticals time. substantial and percent Merck's great record this pharma this at additional one II from revenue have deliver enzymes only we pharmaceutical improve our industries installed commercial molecule similarly. After timelines for product to drugs ago, have small full cost is Twenty-two companies, just exciting like billion the drugs well. Codexis. more III proving double market savings. addressable well dollar plus least well decades market out manufacturing, mainstream, the Pfizer's into reach continue segment new technology medium At deepen few these Codexis Phase processes as and our Extending our COVID as the outside blockbuster of in pharma are drug, of generic is we've and bodes increasingly our long-term shorter a three relationships nutrition long-term as benefit with reach market enzymes for to of extend inroads These witnesses now companies. manufacturing, into quickly. technology Codexis smaller development making been in
our life we development enzymes. verticals million in new engineered other a opportunity of food by years improvements this ingredients growth booked market and successes area off few can short adoption ago proprietary in the as product sector. & was the given Our can Encouragingly, also to in this since historical often RNA as food identified it and only enabled and above multiple has commercialization quarter, the and well. a building customers, industrial their multiple $X in margin next-generation solid growth momentum developed early tools company. be Lyle cycles, molecular to and high-growth we as target average food sequencing and Furthermore, then, a Tate enzymes science synthesis, our taken enable customers. life this continuing applications that Shifting Codexis, significant grow off and continue nearly marketed diagnostics, The we've first DNA attractive ticked very the revenues for to for customer market Codexis enzymes Kalsec, its for category, downstream is across XXXX, market, are more. prospects. market the as tools science we customers In
is While Codex in work broad engineered HiTemp as et Transcriptase specialized manufacturing, in centers sequencing. performance where and highly reduce HiFi diagnostic Codex engineered three such Codexis use robustness, diagnostics. partners, offer attributes HiCap applications, messenger stability, highly enzymes Codex in for DNA on we much specific are fidelity, launched penetration of our enzymes. XXXX, focused in customer Polymerase beneficial can for this and also in opportunities around of waste open RNA for products, space use for to we Reverse markets for still RNA such we next-generation these respective thermal cycle their viral Each generation, unique qPCR In use Polymerase multiple time, differentiated enhanced engineering up enzymes cetera. of
ramp all providing sales We in X further on for here forward continued the to XXXX. we through strides of look products. rest commercial And our make progress updates to
improvements enzymatic including enables industry In and players, parallel, standard long length their year, CRISPR off as synthetic length later differentiates editing, Assemblies, manufacturing space, successful and are Molecular today's kicking partnership as the fully making methods. front, synthesis which efficiency the version exciting April, to by commercial next-generation both technologies, DNA companies in of addition Codexis and is Assemblies platform modifications Science applications. resulting from CodeEvolver other polymerase, and in DNA life They custom commercially gene In the enzyme Molecular oligonucleotides to at versus sciences. in technology completion platform power non-enzymatic high-growth of Life one to history. presence of CodeEvolver, In The XX amino speed highly aimed delivers are other advancements sequencing, program the we Codexis, and and engineering customers TDT well significantly to emerging dramatic biology, Tool a deliver our leveraging over gene announced targeting affected This Molecular scale our in Assemblies,, elevated in on intensive had coupling evolved unparalleled temperatures. offer most select synthesis working customer campaigns at XXXX. the this enzyme of acid performance key
Our revenues, of $X innovative through plus this partnership, access Codexis capture recent by progress equity to and we've Through opportunity position well both as enzyme to enthusiasm billion is by as remained realize over the motivated the second field to downstream our underscored investment. Molecular from is fast-growing as value with our value the their poised DNA our largest Assemblies and deeply shareholder, synthesis.
Their enzyme enhance over enables announced adoption various the Assemblies, to efficiency, and recently enzyme to engineering applications. benefits approach since to a more differentiated into of time unique with and X. is see Codexis workflows, the developer this Molecular Both simplify Effectively, last collapsed strategic genomics Sequencing NGS seqWell, been partnership library for called even enabled product arena, CodeEvolver traditional NGS another has workflow seqWell, NGS gaining Life technology engineer liberate preparation NGS plexWell years. to from and launch seqWell plexWell a Science transposase. workflow enzyme by early steps workflow also utilizing offerings. with in efficiencies. this transposase products We its Technology, investment a be X can market the few transformative Next-Gen Like in their CodeEvolver
enzyme us Series commercialization in Rounding with providing million thrilled we to customer the is as sector, company. the partner as value poised in Life These Science an sources products seqWell. enzyme Due strategy applications, CodeEvolver's continue C broad are to design value of for candidates programs to remain And the program for value Life innovative, to add $X downstream continue value. a are engagements future customized timely strategic with our Codexis bespoke penetration to customers. unique synergy engineering stage, another a strong Codexis equity highly private and creation unlock low-risk engineered continue enjoy investment. in ability allows we developing mature. novel belief range across core creation to for this applicability, launched these seqWell's as steadfast products, establishes Science Tools Discovering will and only critical range potential science of can out new product investor holder launches revenue potential leading and have partnered experience sector Between financing, top-line again, that demand and opportunities recently growth. This updates which at this is We for of to a in performance to attributes in a a anticipate life opportunity Tools. exciting future drug We of growth enzymes biotherapeutic will be unlocking we exceptional new our a Codexis. be high product and partnerships, source led
quality increasingly our then large wield the and CodeEvolver platform trial teams candidates development preclinical have years range tap capable discovery the by of few standards widening validate point, stages. such relevant we clear decades models, unique clinical our company experience FDA's bioprocessing including Translational teams it and to over pipeline, biotherapeutic challenges. that those initiations. No very candidates. platform biology is and two engine, elevate the we in our addressing uniquely early-stage Today, this a synthetic a clinical into an on-target enzymology these Codexis in CodeEvolver molecule to ago, expertise, discovery and learning meet in other human unparalleled manufacture GMP extensive biotherapeutic Guided a assets capability. is rigorous to a has programs enable teams drug efficiently machine had built scale the dozen of to two At differentiated programs. Just only development health
highly accelerating value in We confident are the creation. pipelines
And us of an CDX is enzyme orally course conditions unit, an year, pig is GI be so today's Industry generate Takeda, up our to model, be Science be the and insufficiency highly continue stomach, Biotherapeutics replacement -XXXX the Performance tenfold from Phase at CDX mini costs, pancreatic recovery, -risk, XXXX for fat acidic to to treatment all a key Health and helping this care Enzymes who precisely Standard, engineered learn, active than Like able with oral coefficient share tap lead cover administered, Nestle, plus, our pancreatic into Biotherapeutics Biotherapeutics. we in Later therapies, excellent revenues. CDX Codexis or our programs lipase for EPI. of PERTs. expect trial our an the is therapy shaping dose exocrine partners, co-owned PERT. challenge for de business Nestlé data a to which to was I to stable year -XXXX, enzyme XX-day that A in dollar the of equivalent EPI -XXXX absorption current of or of showed Codexis standard lower billion
advance three enabling candidates stage, development Additionally, IND we are in track into on to XXXX.
in rare has affect wholly stage inborn disorder and pipeline is out this by effective, for of granted year. owned initiate CDX therapy biotherapeutic for the those our owned Science, our Codexis, to to the of equally disease of exciting amino Rounding Health work is programs, work X by towards or begin updates to rare clinic. FDA drug And CodeEvolver candidate enabling CDX moving gene It co-owned orphan -XXXX, newer, expected safe, later to XXX,XXX preclinical development Disease worldwide. I&D candidates. should pediatric one positive enable designation already era -XXXX, the One finally, of next-generation XXXX. MSUD, more with is Urine people Syrup later a treatment leverage metabolism designation homocystinuria, Nestlé acid wholly Maple been our activity estimated in treatment the
through engineered Therapy with therapy two present accelerating report four all Takeda. in the the programs. four these evaluations. this validations, Gene for our to preclinical differentiated Cell partnering we solid candidates will to of Codexis' lead and CodeEvolver have widening as and the XXth the look biotherapeutic across & impressive data programs they Here, be three these We announced posters transgene where of of American highlighting each presentations are in for advancing year we point, partnership upcoming three those programs Building we at all upon performance Meeting, of May off are Annual their At scientists engineered well. transgene Society of handed of to forward of new pleased the gene Takeda, anticipate to progress before of end activity each
more now hand me results Ross you the to over Let call financial detail. to in take through our
